In the CAURAL phase III study (NCT02454933), patients with EGFRm T790M-positive advanced NSCLC with PD after initial EGFR TKI therapy were randomized to receive either osimertinib or osimertinib + durvalumab (54). Here, EGFR is linked to non-small cell lung carcinoma.